Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 60.22B 8.96B 7.68B 7.19B 6.57B 12.4B 854B 12.52B 84.86B 33.03B 431B 33.64B 32.91B 1,427B P/E 2026 *
45.6x
P/E 2027 * 34.6x
Enterprise Value 55.51B 8.26B 7.08B 6.63B 6.06B 11.43B 787B 11.55B 78.23B 30.45B 397B 31.01B 30.34B 1,316B EV / Sales 2026 *
6.87x
EV / Sales 2027 * 5.77x
Free-Float
61.13%
Yield 2026 *
0.8%
Yield 2027 * 1.06%
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 8.12B
-0.59%+1.13%+78.27%+123.89% 1,111B
+0.66%+0.84%+53.23%+64.44% 658B
+0.68%+2.84%+28.29%+81.52% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.68%+5.09%+17.04% 256B
-0.03%+4.43%+53.96%+73.23% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+1.24%+3.65%+30.25%+93.44% 182B
Average +1.01%+4.49%+33.72%+54.33% 421.22B
Weighted average by Cap. +0.63%+4.68%+46.39%+72.72%

Financials

2026 *2027 *
Net sales 8.09B 1.2B 1.03B 966M 882M 1.67B 115B 1.68B 11.39B 4.44B 57.86B 4.52B 4.42B 192B 9.78B 1.46B 1.25B 1.17B 1.07B 2.02B 139B 2.03B 13.79B 5.37B 70.02B 5.47B 5.35B 232B
Net income 1.36B 203M 174M 163M 149M 280M 19.31B 283M 1.92B 747M 9.74B 761M 744M 32.27B 1.79B 267M 229M 214M 196M 369M 25.42B 373M 2.53B 983M 12.83B 1B 980M 42.48B
Net Debt -4.71B -700M -600M -562M -514M -969M -66.76B -979M -6.63B -2.58B -33.68B -2.63B -2.57B -112B -3.73B -555M -475M -445M -407M -768M -52.86B -775M -5.25B -2.04B -26.67B -2.08B -2.04B -88.33B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-